Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Acta Neuropathologica

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF00310917PMID 1659107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alzheimer paired helical filaments: Identification of polypeptides with monoclonal antibodies

  2004cited by this paper
• Alzheimer paired helical filaments: Immunochemical identification of polypeptides

  2004cited by this paper
• Alzheimer neurofibrillary tangles: Monoclonal antibodies to inherent antigen(s)

  2004cited by this paper
• Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis

  2004cited by this paper
• Alzheimer paired helical filaments: Bulk isolation, solubility, and protein composition

  2004cited by this paper
• Biochemical assay of Alzheimer's disease--associated protein(s) in human brain tissue. A clinical study.

  1990cited by this paper
• Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects.

  1990cited by this paper
• Ubiquitin-conjugating enzymes: novel regulators of eukaryotic cells.

  1990cited by this paper
• Amyloid of Alzheimer's disease: Structure-function-relationships and peptide inhibitors of fibril formation

  1990cited by this paper
• The "normal" brain. "Abnormal" ubiquitinilated deposits highlight an age-related protein change.

  1989cited by this paper
• Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease

  1989cited by this paper
• Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease.

  1989cited by this paper
• Identification and localization of a tau peptide to paired helical filaments of Alzheimer disease.

  1989cited by this paper
• Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau.

  1988cited by this paper
• Lack of evidence for dysfunction of the blood-brain barrier in Alzheimer's disease: an immunohistochemical study.

  1988cited by this paper
• Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments.

  1988cited by this paper
• Diagnosis of Alzheimer's disease.

  1988cited by this paper
• Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer??s disease

  1987cited by this paper
• Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.

  1987cited by this paper
• CSF and serum concentrations of albumin and IgG in Alzheimer's disease.

  1987cited by this paper
• Blood-brain barrier in Alzheimer dementia and in non-demented elderly

  1987cited by this paper
• Alzheimer‐related neuronal protein A68: Specificity and distribution

  1987cited by this paper
• Ubiquitin is a component of paired helical filaments in Alzheimer's disease.

  1987cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein? (tau) in Alzheimer cytoskeletal pathology

  1987cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease.

  1986cited by this paper
• Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.

  1986cited by this paper
• Expression cloning of a lymphocyte homing receptor cDNA: ubiquitin is the reactive species.

  1986cited by this paper
• Paired helical filament antigen in CSF.

  1985cited by this paper
• Diagnosis of Alzheimer's disease.

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia.

  1983cited by this paper

• Cerebrospinal fluid ubiquitin as a biomarker for neurodegenerative diseases: A systematic review

  2023cites this paper
• Identification of UBE3A Protein in CSF and Extracellular Space of the Hippocampus Suggest a Potential Novel Function in Synaptic Plasticity

  2021cites this paper
• Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

  2019cites this paper
• Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases

  2018cites this paper
• Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles

  2018cites this paper
• Evaluation of the Endo-Lysosomal System and the Ubiquitin-Proteasome System in Neurodegenerative Diseases

  2018cites this paper
• Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside

  2017cites this paper
• Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

  2017cites this paper
• Advantages of Extracellular Ubiquitin in Modulation of Immune Responses

  2016cites this paper
• Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives.

  2015cites this paper
• Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration.

  2014cites this paper
• CSF ubiquitin as a specific biomarker in Alzheimer's disease.

  2014cites this paper
• Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood

  2012cites this paper
• Extracellular ubiquitin: immune modulator and endogenous opponent of damage‐associated molecular pattern molecules

  2011cites this paper
• Biomarker-based dissection of neurodegenerative diseases.

  2011cites this paper
• Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases.

  2009cites this paper
• Molecular pathology of Alzheimer neurofibrillary

  2009cites this paper
• Extracellular, circulating proteasomes and ubiquitin - incidence and relevance.

  2008cites this paper
• Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.

  2007cites this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cites this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cites this paper
• Serum ubiquitin-protein conjugates in normal subjects and patients with alcoholic liver diseases: immunoaffinity isolation and electrophoretic mobility.

  2002cites this paper
• Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins.

  2001cites this paper
• Evaluation of heme oxygenase-1 as a systemic biological marker of sporadic AD

  2000cites this paper
• Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.

  1998cites this paper
• Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.

  1998cites this paper
• Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease.

  1997cites this paper
• Serum concentrations of free ubiquitin and multiubiquitin chains.

  1997cites this paper
• The τ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments

  1997cites this paper
• Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease

  1996cites this paper
• Ability of ubiquitin radioimmunoassay to discriminate between monoubiquitin and multi-ubiquitin chains.

  1996cites this paper
• A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.

  1995cites this paper
• Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

  1995cites this paper
• Immunoassay for the quantification of intracellular multi-ubiquitin chains.

  1995cites this paper
• Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease

  1995cites this paper
• Markers of neurotoxicity: from behavior to autoantibodies against brain proteins.

  1995cites this paper
• Clinical classification of dementias.

  1995cites this paper
• Altered blood‐brain‐barrier function in Alzheimer's disease?

  1994cites this paper
• Ubiquitin in cerebrospinal fluid: a rapid competitive enzyme‐linked immunoflow assay

  1994cites this paper
• Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels

  1994cites this paper
• Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

  1993cites this paper
• Altered Tau and Neurofilament Proteins in Neuro‐Degenerative Diseases: Diagnostic Implications for Alzheimer's Disease and Lewy Body Dementias

  1993cites this paper
• The blood-brain barrier and cerebral microcirculation in Alzheimer disease.

  1992cites this paper
• Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker.

  1992cites this paper
• Brain Levels of Microtubule‐Associated Protein τ Are Elevated in Alzheimer's Disease: A Radioimmuno‐Slot‐Blot Assay for Nanograms of the Protein

  1992cites this paper
• Brain ubiquitin is markedly elevated in Alzheimer disease.

  1991cites this paper